Hypertension, Pulmonary ArterialPH-HIBANCT01501838
Pulmonary Hypertension Institutional Registry at Hospital Italiano de Buenos Aires
An observational study of Hypertension, Pulmonary Arterial, run by Hospital Italiano de Buenos Aires at 1 site in Argentina.
Trial summary
The purpose of this study is to create a registry of patients with Pulmonary Hypertension who received medical care in the Hospital Italiano of Buenos Aires. Read more about this study
- Who is it for?
- Ages 17 years and older
- Conditions the study is for
- Hypertension, Pulmonary Arterial
- How many people
- 200 participants
- Where
- 1 siteArgentina
- Study dates
- 1 Jan 2017to 1 Jun 2031
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 17 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients who meet inclusion criteria and none of exclusion criteria during the study period are eligible to this study. In the population, the PAH cohort will consist of those incident cases and prevalent cases PAH WHO group 1 aged ≥18 years between January 2017 and December 2030 who attended at Hospital Italiano of Buenos Aires.
Who may be able to join
- Diagnosed with PAH WHO group 1 (2022 ESC/ESR guidelines criteria) as the presence of a mean pulmonary artery pressure (mPAP) greater than 20 mmHg at rest with pulmonary arterial wedge pressure (PAWP) >15 mmHg and pulmonary vascular resistance (PVR) >2 WU, according to the 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.
- Included in the institutional registry of PAH of Hospital Italiano de Buenos Aires
- Aged ≥18 years at the index date.
- Exclusion Criteria History of lung transplantation surgery previously the baseline period
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Argentina1 site, 1 recruiting
- Recruiting
Hospital Italiano de Buenos Aires
Buenos Aires, Buenos Aires, 1181
Ignacio M Bluro, MD, +541149590200 ext. 5303, ignacio.bluro@hiba.org.ar
Ignacio M Bluro, MD
About this study
The purpose of this study is to create a registry of patients with Pulmonary Hypertension who received medical care in the Hospital Italiano of Buenos Aires.
Read the detailed description
The Institutional Registry of Pulmonary Hypertension includes patients prospectively with incident pulmonary hypertension type I. It also includes prevalent cases from our HMO who had diagnosis prior the beginning of the registry.
- Conditions
- Hypertension, Pulmonary Arterial
- Medical subject headings
- Pulmonary Arterial Hypertension
What is being measured
The primary outcome is the main question the study is designed to answer.
Pulmonary Hypertension prevalence
Pulmonary Hypertension prevalence in our community.
Measured: 1 year
Pulmonary Hypertension incidence
Pulmonary Hypertension incidence in our community
Measured: 1 year
Secondary outcomes (1)
Mortality rate
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Dec 2011 (estimated)
- Study start1 Jan 2017
- Primary completion31 Dec 2030 (estimated)
- Study completion1 Jun 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hypertension, Pulmonary ArterialStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hospital Italiano de Buenos Aires
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ignacio M Bluro, Hospital Italiano de Buenos Aires
- Investigators
- Ignacio M Bluro, MD, Principal investigator, Hospital Italiano de Buenos Aires
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01501838
- Sponsor's protocol ID
- 1487
- Acronym
- PH-HIBA
- Status last verified
- Aug 2025
- First submitted
- 16 Jun 2011
- Last updated
- 24 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 24 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pulmonary Hypertension Institutional Registry at Hospital Italiano de Buenos Aires
- ClinicalTrials.gov ID
- NCT01501838
- Acronym / sponsor ID
- PH-HIBA / 1487
- Conditions
- Hypertension, Pulmonary Arterial
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Hospital Italiano de Buenos AiresUniversity, hospital or other
- Study start
- 1 Jan 2017 (actual)
- Primary completion
- 31 Dec 2030 (estimated)
- Study completion
- 1 Jun 2031 (estimated)
- First posted
- 29 Dec 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to create a registry of patients with Pulmonary Hypertension who received medical care in the Hospital Italiano of Buenos Aires.
Detailed description
The Institutional Registry of Pulmonary Hypertension includes patients prospectively with incident pulmonary hypertension type I. It also includes prevalent cases from our HMO who had diagnosis prior the beginning of the registry.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 17 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients who meet inclusion criteria and none of exclusion criteria during the study period are eligible to this study. In the population, the PAH cohort will consist of those incident cases and prevalent cases PAH WHO group 1 aged ≥18 years between January 2017 and December 2030 who attended at Hospital Italiano of Buenos Aires.
Key inclusion criteria (4 listed)
- Exclusion Criteria History of lung transplantation surgery previously the baseline period
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Pulmonary Hypertension prevalence
Time frame: 1 year
Pulmonary Hypertension prevalence in our community.
Pulmonary Hypertension incidence
Time frame: 1 year
Pulmonary Hypertension incidence in our community
1 secondary outcome
Mortality rate
Time frame: 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Aug 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Hypertension, Pulmonary Arterial
Active, not recruitingPhase 1
A Pilot Study of Microbiota Transplant With Antibiotic Preconditioning and Fiber Supplementation in Pulmonary Arterial Hypertension (GUT RESTORE-PAH)
Pulmonary Arterial Hypertension
RecruitingObservational study
Natural History Study of Biomarkers in Pulmonary Arterial Hypertension
Pulmonary Disease, Pulmonary Hypertension
Active, not recruitingPhase 1
Study of Intravenous ZMA001 in Healthy Subjects
Pulmonary Arterial Hypertension PAH
RecruitingPhase 4
Sotatercept in Pulmonary Arterial Hypertension
Pulmonary Artery Hypertension
Recruiting
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
Heart Failure, Heart Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ignacio M Bluro, MD principal investigator
Hospital Italiano de Buenos Aires
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hypertension, Pulmonary Arterial, run by Hospital Italiano de Buenos Aires at 1 site in Argentina.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 24 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Argentina. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ignacio M Bluro, MD (+541149590200 ext. 5303, ignacio.bluro@hospitalitaliano.org.ar), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pulmonary Hypertension prevalence (time frame: 1 year). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Aug 2025.